mProX™ Human NMBR Stable Cell Line

Ganmaa D, et al. "Latent TB Infection, Vitamin D Status and COVID-19 Severity in Mongolian ." Nutrients, 2023.
The aim of this study was to identify potential risk factors for COVID-19 severity among Mongolian inpatients, including serum vitamin D levels and latent TB infection. The study also examined the effects of disease complications and treatment outcomes. It included 270 patients who were admitted to the Mongolian National Center for Communicable Disease, the main referral center for infectious diseases in the country, and diagnosed with COVID-19 through a positive PCR test. Demographic, clinical, and laboratory data were analyzed. Results showed that 46% of patients had mild-to-moderate illness, 32% had severe illness, and 22% had critical illness. Of the 11 patients with active TB, 91% were hospitalized with severe or critical COVID-19, suggesting a higher risk of severe illness (OR = 10.6 [1.2; 92.0] 95% CI). While 32% of patients had severe vitamin D deficiency (25(OH)D < 10 ng/mL), it was not significantly associated with COVID-19 severity (p = 0.65). In contrast, older age, male gender, active TB and/or COPD were associated with increased risk of severe illness, while a history of COVID-19 vaccination and a BCG vaccination scar were found to be protective against severe illness.
Pubmed: 37764763   DOI: 10.3390/nu15183979

Sekizaki T, et al. "Neuromedin B receptor as a potential therapeutic target for corticotroph ." Pituitary, 2023.
The study aimed to evaluate the expression of Neuromedin B (NMB) and NMB receptor (NMBR) in human corticotroph adenomas, and to investigate the effects of NMBR antagonist PD168368 on murine and human corticotroph tumors. Real-time qPCR and immunostaining were performed to assess NMB and NMBR expression in human pathological specimens. Results showed higher expression of NMB and NMBR in corticotroph adenomas compared to non-functional and somatotroph adenomas. PD168368 was found to decrease proopiomelanocortin mRNA and protein levels, as well as ACTH secretion and cell proliferation in murine AtT-20 cells. In mice with tumor xenografts, treatment with PD168368 led to downregulation of tumor growth, ACTH, and corticosterone levels. In patient-derived adenoma cells, PD168368 also reduced POMC mRNA expression and ACTH secretion. Furthermore, PD168368 was shown to suppress the expression of cyclin E, a protein involved in cell proliferation, in both AtT-20 and patient-derived cells. These findings suggest that NMBR antagonist could be a potential treatment for Cushing's disease, possibly through cyclin E suppression.
Pubmed: 37642928   DOI: 10.1007/s11102-023-01350-3